Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Background: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of infl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carlos Taxonera, María Pilar Martínez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, María Teresa Diz-Lois, Ana María Fuentes Coronel, José Lázaro Pérez Calle, Begoña Casis, Rocío Ferreiro-Iglesias, Marta Calvo, David Olivares, Cristina Alba
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/9028789dcdd649f38c8d7504b1e8a2d2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9028789dcdd649f38c8d7504b1e8a2d2
record_format	dspace
spelling	oai:doaj.org-article:9028789dcdd649f38c8d7504b1e8a2d22021-12-01T23:33:50ZPreferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study1756-284810.1177/17562848211056157https://doaj.org/article/9028789dcdd649f38c8d7504b1e8a2d22021-11-01T00:00:00Zhttps://doi.org/10.1177/17562848211056157https://doaj.org/toc/1756-2848Background: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of inflammatory bowel disease (IBD) patients after switching their ADA regimen from 40 mg weekly to 80 mg EOW given with a single-dose pen. Methods: In this multicentre cross-sectional study, patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW completed the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), a four-item questionnaire [a Likert-type 5-point scale for preferences, two closed questions for convenience and a 100-point visual analogue scale (VAS) to assess which escalated ADA regimen patients would prefer to continue] and two Health-Related Quality of Life (HRQoL) questionnaires: the generic European Quality of Life–5 Dimensions (EQ-5D) and disease-specific Spanish version of the Inflammatory Bowel Disease Questionnaire (SIBDQ-9). Results: In total, 77 patients (64 Crohn’s disease and 13 ulcerative colitis) were included. The TSQM score showed a notably high global satisfaction [83.4, standard deviation (SD) = 14.1] of patients with ADA 80 mg EOW given with a single-dose pen, with high TSQM scores for individual components: effectiveness (77.6, SD = 16.9), convenience (83.7, SD = 14.5) and side effects (86.1, SD = 23.4). Most of the patients (74%) preferred the ADA EOW regimen (59.7% had strong preference, 14.3% slight preference). ADA EOW interferes less with daily activity (59.7%) and with travel plans (81.8%). Most patients (77%) would prefer to continue with ADA EOW (mean VAS score of 84.7, SD = 24.1, where 100 indicates a preference for ADA EOW). Patients reported high HRQoL scores on both the EQ-5D (72.3, SD = 20.1) and SIBDQ-9 (75.1, SD = 14.7). Conclusion: IBD patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW reported a higher preference for the EOW regimen and therefore most decided to continue with a single self-injection EOW.Carlos TaxoneraMaría Pilar Martínez-MontielManuel Barreiro-de-AcostaIsabel VeraRufo LorentePablo VegaMaría Teresa Diz-LoisAna María Fuentes CoronelJosé Lázaro Pérez CalleBegoña CasisRocío Ferreiro-IglesiasMarta CalvoDavid OlivaresCristina AlbaSAGE PublishingarticleDiseases of the digestive system. GastroenterologyRC799-869ENTherapeutic Advances in Gastroenterology, Vol 14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Carlos Taxonera María Pilar Martínez-Montiel Manuel Barreiro-de-Acosta Isabel Vera Rufo Lorente Pablo Vega María Teresa Diz-Lois Ana María Fuentes Coronel José Lázaro Pérez Calle Begoña Casis Rocío Ferreiro-Iglesias Marta Calvo David Olivares Cristina Alba Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
description	Background: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of inflammatory bowel disease (IBD) patients after switching their ADA regimen from 40 mg weekly to 80 mg EOW given with a single-dose pen. Methods: In this multicentre cross-sectional study, patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW completed the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), a four-item questionnaire [a Likert-type 5-point scale for preferences, two closed questions for convenience and a 100-point visual analogue scale (VAS) to assess which escalated ADA regimen patients would prefer to continue] and two Health-Related Quality of Life (HRQoL) questionnaires: the generic European Quality of Life–5 Dimensions (EQ-5D) and disease-specific Spanish version of the Inflammatory Bowel Disease Questionnaire (SIBDQ-9). Results: In total, 77 patients (64 Crohn’s disease and 13 ulcerative colitis) were included. The TSQM score showed a notably high global satisfaction [83.4, standard deviation (SD) = 14.1] of patients with ADA 80 mg EOW given with a single-dose pen, with high TSQM scores for individual components: effectiveness (77.6, SD = 16.9), convenience (83.7, SD = 14.5) and side effects (86.1, SD = 23.4). Most of the patients (74%) preferred the ADA EOW regimen (59.7% had strong preference, 14.3% slight preference). ADA EOW interferes less with daily activity (59.7%) and with travel plans (81.8%). Most patients (77%) would prefer to continue with ADA EOW (mean VAS score of 84.7, SD = 24.1, where 100 indicates a preference for ADA EOW). Patients reported high HRQoL scores on both the EQ-5D (72.3, SD = 20.1) and SIBDQ-9 (75.1, SD = 14.7). Conclusion: IBD patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW reported a higher preference for the EOW regimen and therefore most decided to continue with a single self-injection EOW.
format	article
author	Carlos Taxonera María Pilar Martínez-Montiel Manuel Barreiro-de-Acosta Isabel Vera Rufo Lorente Pablo Vega María Teresa Diz-Lois Ana María Fuentes Coronel José Lázaro Pérez Calle Begoña Casis Rocío Ferreiro-Iglesias Marta Calvo David Olivares Cristina Alba
author_facet	Carlos Taxonera María Pilar Martínez-Montiel Manuel Barreiro-de-Acosta Isabel Vera Rufo Lorente Pablo Vega María Teresa Diz-Lois Ana María Fuentes Coronel José Lázaro Pérez Calle Begoña Casis Rocío Ferreiro-Iglesias Marta Calvo David Olivares Cristina Alba
author_sort	Carlos Taxonera
title	Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
title_short	Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
title_full	Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
title_fullStr	Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
title_full_unstemmed	Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
title_sort	preferences and satisfaction of ibd patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the adascal study
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/9028789dcdd649f38c8d7504b1e8a2d2
work_keys_str_mv	AT carlostaxonera preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT mariapilarmartinezmontiel preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT manuelbarreirodeacosta preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT isabelvera preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT rufolorente preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT pablovega preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT mariateresadizlois preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT anamariafuentescoronel preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT joselazaroperezcalle preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT begonacasis preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT rocioferreiroiglesias preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT martacalvo preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT davidolivares preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy AT cristinaalba preferencesandsatisfactionofibdpatientsafterswitchingfromadalimumab40mgweeklyto80mgeveryotherweekgivenasasingleinjectiontheadascalstudy
_version_	1718403998827937792

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Ejemplares similares